News Quantified

IRWD – ironwood pharmaceuticals, inc. - class a (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Ironwood Pharmaceuticals (NASDAQ:IRWD) had its "sell (d)" rating reaffirmed by analysts at Weiss Ratings.

What Catalysts Are Shaping the Changing Narrative for Ironwood Pharmaceuticals? [Yahoo! Finance]

Ironwood Pharmaceuticals: Today's Gains Seem Sustainable After Disastrous First Half Of 2025 [Seeking Alpha]

Ironwood Pharmaceuticals (NASDAQ:IRWD) had its price target raised by analysts at Wells Fargo & Company from $1.00 to $3.00. They now have an "equal weight" rating on the stock.

Ironwood Pharmaceuticals Non-GAAP EPS of $0.24 beats by $0.12, revenue of $122.06M beats by $46.36M [Seeking Alpha]

17.7%

BEAT

-13.0%

MISS

-8.0%

MISS

-12.4%

MISS

Form 8-K IRONWOOD PHARMACEUTICALS For: Dec 18

Form 4 IRONWOOD PHARMACEUTICALS For: Dec 15 Filed by: DENNER ALEXANDER J

Form 8-K IRONWOOD PHARMACEUTICALS For: Nov 25

Form 4 IRONWOOD PHARMACEUTICALS For: Nov 17 Filed by: Gaskins Tammi L

Form 144 IRONWOOD PHARMACEUTICALS Filed by: Gaskins Tammi L

Top News Gainers

5/16 Form SC 13D IRONWOOD PHARMACEUTICALS Filed by: Sarissa Capital Management LP 11.5%

4/14 Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 7.5%

2/26 Ironwood Pharmaceuticals Announces Publication of Positive IW-3718 Phase IIb Data in Gastroenterology 7.5%

10/31 Q3/2019 9/30/2019 EPS 0.400 ZacksConsensus 0.100 ActVsEst 0.300 - Beat 6.5%

1/6 Ironwood and Allergan Announce Settlement Resolving LINZESS® (linaclotide) Patent Litigation 6.3%

9/11 Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 5.8%

2/29 Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 5.4%

2/13 Q4/2019 12/31/2019 EPS 0.300 ZacksConsensus 0.220 ActVsEst 0.080 - Beat 4.9%

5/31 Form 4 IRONWOOD PHARMACEUTICALS For: May 29 Filed by: Dreyfus Andrew 4.5%

8/13 Ironwood Pharmaceuticals and Alnylam Pharmaceuticals Enter U.S. GI Disease Education and Promotional Agreement for Alnylam’s Givosiran in Acute Hepatic Porphyria (AHP) 3.9%

Top News Decliners

3/17 Form 4 IRONWOOD PHARMACEUTICALS For: Mar 13 Filed by: Dreyfus Andrew -10.8%

7/31 Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $12.00 price target on the stock, up previously from $11.00. -9.1%

2/14 Form SC 13G/A IRONWOOD PHARMACEUTICALS Filed by: BROWN CAPITAL MANAGEMENT LLC -6.2%

6/18 Form 4 IRONWOOD PHARMACEUTICALS For: Jun 14 Filed by: Dreyfus Andrew -5.9%

6/13 Form 8-K IRONWOOD PHARMACEUTICALS For: Jun 11 -5.5%

8/6 Ironwood Pharmaceuticals Announced Proposed Offering of $330 Million of Convertible Senior Notes -5.2%

3/2 Form 4 IRONWOOD PHARMACEUTICALS For: Feb 27 Filed by: MacDonald Kelly -3.6%

10/17 Ironwood Pharmaceuticals to Host Third Quarter 2019 Investor Update Call -3.5%

8/13 Ironwood Pharmaceuticals Announces Full Exercise of Convertible Notes Over-Allotment -3.5%

4/15 Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) had its price target lowered by analysts at Morgan Stanley from $13.00 to $12.00. They now have an "equal weight" rating on the stock. -3.2%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day